盐酸克林霉素对妇科急性盆腔炎治疗效果研究  

Effect of clindamycin hydrochloride on the treatment of gynecological acute pelvic inflammatory disease

作　　者：尚玉红 王景超 孙智善 SHANG Yuhong;WANG Jingchao;SUN Zhishan(Kenli Sub-District Office of Kenli District,Dongying City Community Health Service Center(Kenli Sub-District Office of Maternal and Child Health and family Planning Service Station)Obstetrics and Gynecology,Dongying 257500,China;Shandong University of Traditional Chinese Medicine,Jinan 250000,China;Department of Neurosurgery,Weifang People's Hospital,Weifang 261000,China)

机构地区：[1]东营市垦利区垦利街道办事处社区卫生服务中心(垦利街道办事处妇幼保健计划生育服务站)妇产科,山东东营257500 [2]山东中医药大学,山东济250000南 [3]潍坊市人民医院神经外科,山东潍坊261000

出　　处：《中华灾害救援医学》2024年第10期1200-1203,共4页Chinese Journal of Disaster Medicine

基　　金：2024年山东省职工与职业教育重点课题(2024-089)。

摘　　要：目的探讨在基层医院采用盐酸克林霉素治疗急性盆腔炎的临床价值。方法随机纳入2021年1月至2023年12月在东营市垦利区社区卫生服务中心就诊的120例急性盆腔炎患者,根据随机数字表法分为观察组和对照组,每组各60例。对照组患者给予头孢曲松+甲硝唑;观察组患者给予头孢曲松+甲硝唑+盐酸克林霉素,比较两组患者临床症状改善时间、炎症因子水平、临床疗效和安全性。结果观察组白带、月经恢复正常所用时间,以及子宫压痛、腰骶疼痛、下腹坠胀消失时间均短于对照组(P均<0.001)。治疗前,两组患者炎症指标血清内C反应蛋白(C-Reactionprotein,CRP)、转化生长因子-β(Transforming Growth Factor-β,TGF-β)、白介素-18(Interleukin-18,IL-18)均无显著差异(P>0.05);治疗后,各项炎症指标均改善(P<0.001),且观察组CRP、IL-18水平低于对照组(P<0.001),TGF-β水平高于对照组(P<0.001)。观察组临床总有效率95.00%(57/60),高于对照组的76.67%(46/60)(P<0.05)。观察组不良反应总发生率为5.00%(3/60),与对照组的11.67%(7/60)相比,无显著差异(P>0.05)。结论盐酸克林霉素可有效改善急性盆腔炎的临床症状和体征,控制炎症的进展,且不良反应少,与头孢曲松+甲硝唑联用治疗急性盆腔炎疗效理想。Objective To explore the clinical value of using clindamycin hydrochloride in the treatment of acute pelvic inflammatory disease in primary hospitals.Methods 120 patients with acute pelvic inflammatory disease who visited the Community Health Service Center in Kenli District,Dongying City from January 2021 to December 2023 were randomly included.They were divided into an observation group and a control group using a random number table method,with 60 patients in each group.The control group patients were given ceftriaxone and metronidazole;Observation group patients were given ceftriaxone+metronidazole+clindamycin hydrochloride,and the clinical symptom improvement time,inflammatory factor levels,clinical efficacy,and safety were compared between the two groups of patients.Results The observation group had a shorter time for the recovery of vaginal discharge and menstruation,as well as the disappearance of uterine tenderness,lumbosacral pain,and lower abdominal bloating compared to the control group(P<0.001).Before treatment,there was no significant difference in inflammatory markers such as C-reactive protein(CRP),transforming growth factor-β(TGF-β),and interleukin-18(IL-18)between the two groups of patients(P>0.05);After treatment,all inflammatory indicators improved(P<0.001),and the levels of CRP and IL-18 in the observation group were lower than those in the control group(P<0.001),while the level of TGF-βwas higher than that in the control group(P<0.001).The total clinical effective rate of the observation group was 95.00%(57/60),which was higher than the control group's 76.67%(46/60)(P<0.05).The total incidence of adverse reactions in the observation group was 5.00%(3/60),which was not significantly different from the 11.67%(7/60)in the control group(P>0.05).Conclusion Clindamycin hydrochloride can effectively improve the clinical symptoms and signs of acute pelvic inflammatory disease,control the progression of inflammation,and have fewer adverse reactions.The combination therapy with ceftriaxone and metr

关 键 词：盆腔炎性疾病 炎症趋化因子类 临床方案 

分 类 号：R711[医药卫生—妇产科学]